We have shown that an anti‐hTAPBPL mAb significantly inhibits tumor growth in vivo, with a concomitant increase in tumor‐infiltrating CD4+ and CD8+ T cells and a decrease in the percentage of Tregs. Here, CD8A is linked to neoplasm.